When should romiplostim be considered in patients with heparin‑induced thrombocytopenia?

Romiplostim is NOT indicated for HIT patients

Romiplostim should not be considered for heparin-induced thrombocytopenia (HIT) patients, as it is not indicated for this condition and does not address the underlying pathophysiology of HIT.

Why Romiplostim is Inappropriate for HIT

Mechanism Mismatch

• HIT is a prothrombotic immune reaction, not a platelet production disorder 1, 2
• HIT is mediated by IgG antibodies targeting platelet factor 4 (PF4)-heparin complexes, causing massive platelet activation, explosive thrombin generation, and thrombosis 2
• Thrombocytopenia in HIT results from platelet consumption through activation and removal by the mononuclear phagocyte system—not from decreased production 2

Romiplostim's Mechanism

• Romiplostim increases platelet production by binding and activating the TPO receptor 3
• This mechanism is fundamentally wrong for HIT, where the problem is platelet destruction and hypercoagulability, not inadequate production
• Adding more platelets to a prothrombotic state could theoretically worsen thrombotic complications

FDA-Approved Indications for Romiplostim

Romiplostim is FDA-approved for 3:

• Immune thrombocytopenia (ITP) - where platelet destruction exceeds production
• Chemotherapy-induced thrombocytopenia (CIT) - where chemotherapy suppresses platelet production 4
• Acute radiation syndrome - where radiation damages bone marrow production

HIT is notably absent from this list.

Correct Management of HIT

When HIT is suspected or confirmed 1, 2:

1. Immediately discontinue all heparin (UFH and LMWH)

2. Start alternative anticoagulation with non-heparin agents:

   • Argatroban
   • Bivalirudin
   • Fondaparinux
   • Direct oral anticoagulants (DOACs) in select cases

3. Do NOT use platelet transfusions unless life-threatening bleeding occurs

4. Do NOT wait for laboratory confirmation before stopping heparin and starting alternative anticoagulation

Critical Pitfall

The thrombocytopenia in HIT is a marker of the disease, not the primary problem. The primary concern is thrombosis risk (occurring in one-third to one-half of HIT cases), which can be limb- or life-threatening 1. Attempting to raise platelet counts with romiplostim misses the point entirely and provides no protection against thrombotic complications.

When Romiplostim IS Appropriate

Consider romiplostim for:

• ITP patients with platelet counts requiring intervention 5, 6, 7
• CIT patients with persistent thrombocytopenia (platelets <85-100 × 10⁹/L) preventing chemotherapy continuation 4, 8
• Starting dose typically 1-4 mcg/kg subcutaneously weekly, titrated to maintain platelets 50-200 × 10⁹/L 3, 9